Special Issue

Epithelial-to-Mesenchymal Transition (EMT) in Cancer

Message from the Guest Editor

Epithelial-to-mesenchymal transition (EMT) is an important event in embryonic development; the transition of epithelial cells to mesenchymal cells allows the formation of adult tissues and organs. EMT is modulated at different levels of control, such as transcriptional control, epigenetic modifications, alternative splicing, translational regulation and microRNA-mediated gene silencing. Moreover, the cellular trans-differentiation from epithelial to mesenchymal states is regulated by many signaling pathways, of which the Ras-ERK, MAPK and TGF- pathways are among the best characterized. These pathways trigger the activation of key transcription factors that serve as master regulators of cell–cell adhesion, cell polarity, and motility. However, despite the intense research for last twenty years, our knowledge is very limited about how all these components regulate the transition. More research is necessary to understand the EMT mechanism and it will help us to identify appropriate drug target. This special issue will discuss the different aspect of EMT.

Guest Editor

Dr. Amit Bera
Atlantic Cancer Research Institute, Moncton, NB E1C 8X3, Canada

Deadline for manuscript submissions

closed (30 June 2021)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/71750

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).